Rigel Pharmaceuticals, Inc. Common Stock RIGL
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T01:27:37.421Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T22:00:14.679716343Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T01:27:36.876581+00:00
Rigel Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 34.08 | 301.6% | 31.2% | |||
| 25Δ | 37.79 | 236.5% | 23.2% | |||
| 30Δ | 41.51 | 171.3% | 15.1% | |||
| 35Δ | 43.52 | 131.9% | 10.5% | |||
| 40Δ | ||||||
| 45Δ | 45.69 | 104.5% | 6.5% | |||
| 50Δ | ||||||
| 55Δ | ||||||
| 60Δ | 47.48 | 70.2% | 2.8% | |||
| 65Δ | 44.60 | 68.8% | 2.8% | 47.98 | 64.4% | 2.0% |
| 70Δ | 44.20 | 59.6% | 1.9% | 49.43 | 81.7% | 2.1% |
| 75Δ | 50.87 | 87.6% | 1.7% | |||
| 80Δ | 53.62 | 107.6% | 1.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 34.08
- IV
- 301.6%
- B/E move
- 31.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 37.79
- IV
- 236.5%
- B/E move
- 23.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 41.51
- IV
- 171.3%
- B/E move
- 15.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 43.52
- IV
- 131.9%
- B/E move
- 10.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 45.69
- IV
- 104.5%
- B/E move
- 6.5%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 47.48
- IV
- 70.2%
- B/E move
- 2.8%
65Δ
- Pseudo strike
- 44.60
- IV
- 68.8%
- B/E move
- 2.8%
- Pseudo strike
- 47.98
- IV
- 64.4%
- B/E move
- 2.0%
70Δ
- Pseudo strike
- 44.20
- IV
- 59.6%
- B/E move
- 1.9%
- Pseudo strike
- 49.43
- IV
- 81.7%
- B/E move
- 2.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 50.87
- IV
- 87.6%
- B/E move
- 1.7%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 53.62
- IV
- 107.6%
- B/E move
- 1.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 66.23% | |
| 61.26% | |
| 61.84% | |
| 63.64% | |
| 64.04% | |
| 68.35% | |
| 66.05% | |
| 65.30% | |
| 64.42% | |
| 65.66% |
Biotechnology
RLAY
Relay Therapeutics, Inc. is a clinical-stage precision drug company. The company is headquartered in Cambridge, Massachusetts.
More →RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the…
More →RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and…
More →ROIV
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that…
More →RPRX
Description unavailable
More →RVMD
Description unavailable
More →